Molecular Signature of Human Virus Specific Effector CD8+ T Cells (83.20)

Rama S Akondy,Joseph D Miller,Gregory Doho,Hong Wu,Michael Zilliox,Carlos de Rio,Mark J Mulligan,Srilatha Edupuganti,W. Nicholas Haining,Rafi Ahmed
DOI: https://doi.org/10.4049/jimmunol.182.supp.83.20
2009-01-01
The Journal of Immunology
Abstract:Evaluation of the cellular immune response soon after an infection is difficult in humans. In consequence, most of our current understanding of the differentiation of an antiviral CD8+ T cell response derives from either total T cells or from cross sectional studies or from various persistent or recurring viral infections. Effective live viral vaccines like the 17D strain of yellow fever virus (YF-17D) model a primary acute viral infection and present an opportunity to study the attributes of an anti-viral CD8+ T cell response in humans. The activation markers HLA-DR and CD38 have been previously shown to identify effector CD8+ T cells after a primary vaccination (Miller et al, 2008). We use these markers to isolate YF-17D specific effectors from human vaccinees. This effector population is transient, appears only during an anti-viral response and contains mostly YF-17D specific CD8+ T cells. Gene chip analysis of these cells shows that effectors undergo dramatic reprogramming as evidenced by changes in the number of genes (~4000) and their expression (effector / naïve fold change from +100 to -26) when compared to naïve CD8+ T cells. This signature is distinct not only from naïve CD8+ T cells but also from the TCM, TEM, and TEMRA memory subsets. We also show that the effector gene expression profile is fairly conserved when compared to the mouse LCMV effectors. One of the many uses of this signature is to understand and identify factors involved in naïve to effector cell differentiation. This research was supported by NIH/NIAID (U19 AI057266).
What problem does this paper attempt to address?